Yilun Wei, Jinhe Xu, Xiulian Huang, Siting Xie, Ping Lin, Chenxi Wang, Yuxin Guo, Shumei Zou, Zhongquan Zhao, Wen Wen, Yingfang Song, Zhenming Bao, Lei Zhang, Wei Liu, Wencui Kong, Wenwu Wang, Baochang He, Shenghang Zhang, Chengzhi Zhou, Ying Chen, Zongyang Yu
BACKGROUND: Programmed cell death-ligand 1 (PD-L1) expression and other biomarkers are not completely reliable predictors of the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC). We investigated the value of peripheral serological inflammatory indicators and their combination in predicting the prognosis of patients with advanced NSCLC treated with checkpoint inhibitors. METHODS: This study retrospectively analyzed 116 NSCLC patients treated with anti-programmed cell death protein 1 (PD-1)/PD-L1 monoclonal antibodies...
April 28, 2023: Journal of Thoracic Disease